



## **NEWS RELEASE**

**Pfizer Limited revenues (on a like to like basis) increases by 12% for the year ended March 31, 2015**

**Results not comparable as the effect for amalgamation has been given during the year ended March 31, 2015**

Pfizer Limited announced its audited results for the year ended March 31, 2015.

### **Amalgamation of Wyeth Limited**

The Scheme of Amalgamation of Wyeth Limited with Pfizer Limited had become effective on December 1, 2014 ("Effective Date"). The appointed date is April 1, 2013.

The effect of amalgamation has been given in the results for the current quarter, sequential quarter and the year ended March 31, 2015. The results are not strictly comparable as the previous year quarter and year end are standalone Pfizer Limited results.

### **Revenues**

A like to like comparison, reflects revenue of ₹1828 crore for the year ending March 31, 2015 as compared to ₹1632 crore for the same period last year, reflecting a growth of 12%.

### **Profits before other income, exceptional items and tax**

Profit from operations (before other income, exceptional items and tax) for the year is ₹252 crore.

EBITDA for the year is at 21%.

Higher expenses and depreciation / amortization arising on amalgamation have impacted the profit from operations for the year.

Excluding one off / incremental expenses, the EBITDA would be at 24%.

### **Exceptional items**

The company had announced a voluntary retirement scheme during the year in its Plant at Thane. Expenses in relation to VRS and other related costs are reflected as Exceptional item.



### **Profit after tax**

Profit after tax has been impacted by comparatively lower bank interest income and higher expenses. The profit after tax is further impacted by depreciation / amortization on assets (goodwill, intangibles and tangible) arising out of amalgamation ₹118 crore for the financial year 2013-14 and 2014-15 respectively. Profit for the year after the impact of amalgamation is ₹70 crore.

### **Dividend**

The Board has recommended dividend of ₹12.5 per equity share of ₹10 each (125%) during the financial year ended March 31, 2015.

### **Contacts -**

#### **Investors:**

**Prajeet Nair**

PfizerLimited

Ph: +91-22-66932352

Email: [prajeet.nair@pfizer.com](mailto:prajeet.nair@pfizer.com)

#### **Media:**

**Harsh Sheth / Samantha D'Souza**

MSL Group

Ph: +91-9870631557 / +91-9920238249

Email: [harsh.sheth@mslgroup.com](mailto:harsh.sheth@mslgroup.com) / [samantha.dsouza@mslgroup.com](mailto:samantha.dsouza@mslgroup.com)

### **About Pfizer Limited:**

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 60 years in India, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at [www.pfizerindia.com](http://www.pfizerindia.com)

### **Disclaimer**

The information contained in this press release is only current as of its date. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care of in the press release and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this press release or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries where such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this press release, independent consultation / advise may be obtained and necessary due diligence, investigation etc. may be done at your end.